Cuba Leads Global Efforts Against COVID-19 in Spite of Blockade
Countries from across the globe have asked Cuba for the recombinant human Interferon Alpha 2B, marketed as Heberon® Alfa R, a drug developed in Cuba proven to be an effective against COVID-19
A Cuban drug, known as the Interferon Alpha 2B, could save thousands of lives in the COVID-19 pandemic. The drug has been produced in China since January 25 and, so far, has managed to effectively cure more than 1,500 patients from the coronavirus. It is one of 30 drugs chosen by the Chinese National Health Commission to combat the respiratory disease.
The recombinant human interferon alpha-2b was first developed in 1986 by a team of researchers from the Centre for Genetic Engineering and Biotechnology (CIGB) and has benefited thousands of Cuban patients since its introduction into the national health system. It is marketed as Heberon® Alfa R. It has been used as a treatment for HIV-AIDS, Hepatitis B and C, Herpes zoster or Shingles, Dengue and different types of cancers. The medication increases the natural production of interferon in the human body and strengthens the immune system of patients, thus, is effective in treating the coronavirus disease.
The drug, developed in Cuba, is produced in China at the Changchun Heber Biological Technology, located in Jilin province, in a joint venture as part of an agreement between the two socialist countries in biotechnology.
It has prevented thousands of deaths in South Korea. Out of the 8,000 infected peoples, only 72 died. Germany has also bought these antivirals from the ChangHeber to fight the pandemic. Out of the 3,156 infected people, only 3 died.
After the effectiveness of the Cuban drug was known and popularized, the country has been flooded with purchase orders for Interferon Alpha 2B from across the globe. Several Latin American, Caribbean and European countries have requested medical aid from Cuba in order to fight the coronavirus outbreak.
In a press conference on March 14, the president of the pharmaceutical company BioCubaFarma group, Eduardo Martinez, indicated that the production of the drug is set to increase significantly after receiving requests from a large number of countries. Martinez assured that the CIGB has enough supplies to meet the needs of the international market, without putting at risk the amounts required by its own country.
SOURCE ⇒ PEOPLESDISPATCH
Please Copy/Paste Article Address to
Share On Your Social Media. Thank-you!
Consider supporting AMIBC™. Contribute by clicking on the advertisers and sponsors featured on AMIBC™ and please utilize them. Readers from around the world, like you, make our work possible. We need your support to deliver quality, vetted, investigative journalism – and to keep it open for everyone. At a time when factual, honest reporting is critical, your support is essential in protecting our editorial independence.
The narratives and issues impacting all Americans is tantamount to the AMIBC™ platform. Every contribution, however big or small, is valuable for our future. Make sure to join the AMIBC Founders Club to maximize the total advantage of being a subscriber.
American Internet Broadcasting™ Corp
All Rights Reserved ® & © 2020
